Celano Michael 4

What Happened Michael Celano, Chief Financial Officer of Larimar Therapeutics (LRMR), received equity awards on January 26, 2026: 37,604 restricted stock units (RSUs) and 225,622 additional derivative awards. Both grants were reported at $0.00 per share (no cash paid at grant), so the reported acquisition value is $0.

Key Details

• Transaction date: 2026-01-26; Form filed: 2026-01-27.
• Awards: 37,604 RSUs (each RSU represents a contingent right to one share on settlement) and 225,622 derivative awards reported as acquired at $0.00.
• Vesting/conditions: The larger derivative award is subject to a vesting schedule — 25% vests on Jan 26, 2027, then the remaining 75% vests in equal monthly installments over the next 36 months, contingent on continued service.
• Post-transaction holdings: The filing excerpt provided does not state total shares owned after these grants.
• Filing timeliness: Filed the day after the transaction date; no late filing indicated.

Context These were equity compensation grants, not open‑market purchases or sales. RSUs and time‑vesting derivative awards are common retention/compensation tools; they do not represent immediate cash proceeds or share sales and generally convert to shares only as they vest and any settlement conditions are met.